Diabetic cardiomyopathy (DCM) is one of the many complications of diabetes. DCM leads to cardiac insufficiency and myocardial remodeling and is the main cause of death in diabetic patients. Abnormal lipid metabolism plays an important role in the occurrence and development of DCM. Huangqi Shengmai Yin (HSY) has previously been shown to alleviate signs of heart disease. Here, we investigated whether HSY could improve cardiomyopathy caused by type 1 diabetes mellitus (T1DM) and improve abnormal lipid metabolism in the diabetic heart. Streptozotocin (STZ) was used to establish the T1DM mouse model, and T1DM mice were subsequently treated with HSY for eight weeks. The changes in the cardiac conduction system, histopathology, blood myocardial injury indices, and lipid content and expression of proteins related to lipid metabolism were evaluated. Our results showed that HSY could improve electrocardiogram; decrease the serum levels of CK-MB, LDH, and BNP; alleviate histopathological changes in cardiac tissue; and decrease myocardial lipid content in T1DM mice. These results indicate that HSY has a protective effect against T1DM-induced myocardial injury in mice and that this effect may be related to the improvement in myocardial lipid metabolism.
Keyphrases
- glycemic control
- type diabetes
- left ventricular
- diabetic rats
- heart failure
- fatty acid
- high fat diet induced
- mouse model
- oxidative stress
- insulin resistance
- high glucose
- cardiovascular disease
- poor prognosis
- drug induced
- high fat diet
- endothelial cells
- metabolic syndrome
- risk assessment
- pulmonary hypertension
- mass spectrometry
- atrial fibrillation
- adipose tissue
- skeletal muscle
- risk factors
- single molecule
- high resolution
- stress induced